Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Purchased by Atria Investments Inc

Atria Investments Inc raised its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 6.9% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,365 shares of the biopharmaceutical company’s stock after purchasing an additional 737 shares during the quarter. Atria Investments Inc’s holdings in Agios Pharmaceuticals were worth $373,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the business. Quest Partners LLC lifted its holdings in Agios Pharmaceuticals by 139.6% during the 3rd quarter. Quest Partners LLC now owns 2,202 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 1,283 shares during the last quarter. Intech Investment Management LLC bought a new position in Agios Pharmaceuticals during the 3rd quarter worth approximately $892,000. Charles Schwab Investment Management Inc. lifted its holdings in Agios Pharmaceuticals by 1.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 465,620 shares of the biopharmaceutical company’s stock worth $20,687,000 after buying an additional 8,093 shares during the last quarter. Fisher Asset Management LLC lifted its holdings in Agios Pharmaceuticals by 20.5% during the 3rd quarter. Fisher Asset Management LLC now owns 855,328 shares of the biopharmaceutical company’s stock worth $38,002,000 after buying an additional 145,416 shares during the last quarter. Finally, Loomis Sayles & Co. L P lifted its holdings in Agios Pharmaceuticals by 36.4% during the 3rd quarter. Loomis Sayles & Co. L P now owns 612,366 shares of the biopharmaceutical company’s stock worth $27,208,000 after buying an additional 163,503 shares during the last quarter.

Insider Activity

In other news, insider Tsveta Milanova sold 2,804 shares of Agios Pharmaceuticals stock in a transaction on Monday, January 6th. The stock was sold at an average price of $32.18, for a total transaction of $90,232.72. Following the transaction, the insider now directly owns 18,906 shares in the company, valued at approximately $608,395.08. This trade represents a 12.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.93% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms have commented on AGIO. Scotiabank increased their target price on Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, December 9th. HC Wainwright initiated coverage on Agios Pharmaceuticals in a report on Monday, February 24th. They issued a “buy” rating and a $58.00 price target on the stock. StockNews.com downgraded Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Wednesday, December 18th. Finally, Royal Bank of Canada raised their price target on Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $56.57.

Agios Pharmaceuticals Price Performance

AGIO opened at $30.93 on Monday. Agios Pharmaceuticals, Inc. has a 12 month low of $27.14 and a 12 month high of $62.58. The stock has a market cap of $1.77 billion, a P/E ratio of 2.73 and a beta of 0.90. The stock’s 50 day moving average price is $33.70 and its 200 day moving average price is $41.76.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a net margin of 1,845.92% and a negative return on equity of 2.51%. Equities analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.